Background
==========

Anaphylactic reactions caused by hymenoptera stings -- predominantly bee, wasp or paperwasp -- stings are a common medical problem and account for approximately 40 deaths per year in the United Sates \[[@B1],[@B2]\]. They belong to the most dramatic allergic diseases and may present with an acute onset of combined local and systemic symptoms.

The prevalence of insect-sting allergies varies between 0.4 to 4% and more \[[@B3]-[@B6]\], and the rate of mortality has been reported to be between 0.09 to 0.45/1000000 people/year \[[@B4],[@B5],[@B7]\].

It is generally accepted that these systemic reactions to insect stings, even if non-fatal, represent extremely unpleasant and dangerous situations. Therefore, many patients would benefit physically and psychologically from a preventive treatment. In general, the patients would prefer a long-term treatment rather than experiencing emergency medication and an everlasting fear about upcoming events. However, in consideration of the relatively low mortality rate reported, many physicians do not refer the patients to further detailed investigations. The presently available preventive treatment in form of specific immunotherapy is therefore often neglected. Also, a lack of knowledge of immunotherapy or limited access may be additional factors.

Apart from fire ants and mosquitoes in America, the sub-order of hymenoptera aculeatae accounts for most allergic reactions in Europe \[[@B8],[@B9]\]. A large number of studies on the prevalence and mortality of anaphylactic sting reactions, the differentiation between venoms and the impact of specific immunotherapy have been performed for industrialized western countries so far. However, hymenoptera allergies have been recognized as a worldwide health hazard, reaching also the developing countries but detailed studies for these regions have not been reported so far. In this respect, the present study was conducted to investigate the impact of Rush-SIT in a population of Albanian hymenoptera allergy patients which were treated with Rush-SIT.

Methods
=======

Subjects
--------

The present cohort consists of files collected from 37 patients who were treated with Rush-SIT for hymenoptera sting allergy at the university hospital of Tirana between the period of 1987 to 1996. All study subjects were native Albanians. Before 1987, all patients were treated with whole body extracts and therefore excluded from the study.

Evaluation of subjects
----------------------

For the assessment of the patients\' history, general data (sex, age), the age when the sting reactions happened, time of stinging (date or month), place of stings, number of sting-episodes, identity of insect (if possible), and symptoms after sting episode were evaluated.

Tests
-----

The tests consisted of intracutaneous tests in concentrations of 0.001, 0.01, 0.1 and 1 μg/ml venom from bees (apinae), wasps (vespidae, subfamily vespinae) or paperwasps (vespidae, subfamily polistinae). Positive test results were accepted from induration diameters of at least 5 mm.

Specific rush immunotherapy (Rush-SIT)
--------------------------------------

The Rush-SIT treatment was performed during a 4-day hospital stay, in which a standardized scheme of escalating doses of venom was administered subcutaneoulsy: The doses were increased from 10 ^-2^ to 100 μg/ml of venom (Table [1](#T1){ref-type="table"}). The patients in the present study only received a single venom type, and subcutaneous maintenance injections of 100 μg venom were performed after 7 d, 14 d and monthly for a period of 3 years.

###### 

Scheme of venom rush immunotherapy. The Rush-SIT treatment was according to a 4-day scheme with increasing doses of 10 ^-2^ to 100 μg/ml of venom.

  **Day I**     **Day II**                                                                                    
  ------------- ----------------- --------------- ----------------- ------- ----------------- --------------- -----------------
  Time          Conc. \[μg/ml\]   Volume \[ml\]   Quantity \[μg\]   Time    Conc. \[μg/ml\]   Volume \[ml\]   Quantity \[μg\]
                                                                                                              
  08.30         0.01              0.05            0.0005            08.30   1.0               0.05            0.05
  09.00         0.01              0.10            0.001             09.00   1.0               0.10            0.1
  09.30         0.01              0.20            0.002             09.30   1.0               0.20            0.2
  10.00         0.01              0.40            0.004             10.00   1.0               0.40            0.4
  10.30         0.10              0.05            0.005             10.30   10.0              0.05            0.5
  11.00         0.10              0.10            0.01              11.00   10.0              0.10            1.0
  11.30         0.10              0.20            0.02              11.30   10.0              0.20            2.0
  12.00         0.10              0.40            0.04              12.00   10.0              0.40            4.0
  12.30         1.00              0.05            0.05              12.30   100.0             0.05            5.0
                                                                                                              
  **Day III**   **Day IV**                                                                                    
                                                                                                              
  Time          Conc. \[μg/ml\]   Volume \[ml\]   Quantity \[μg\]   Time    Conc. \[μg/ml\]   Volume \[ml\]   Quantity \[μg\]
                                                                                                              
  08.30         100.0             0.05            5.0               08.30   100.0             1.00            100.0
  09.00         100.0             0.10            10.0                                                        
  09.30         100.0             0.20            20.0                                                        
  10.00         100.0             0.40            40.0                                                        
  10.30         100.0             0.60            60.0                                                        
  11.00         100.0             0.80            80.0                                                        
  11.30         100.0             1.00            100.0                                                       

In case of subjective or objective adverse reactions, the further treatment was dependent on the type of reaction as previously described \[[@B10]\]: Mild subjective reactions were followed by the application of the same dose before an increase. Objective reactions were followed by treatment of the symptoms and a period of one day without further venom application before starting with a reduced dose.

Anaphylactic reactions
----------------------

Anaphylactic reactions during Rush-SIT were classified according to the criteria of Mueller into 4 degrees \[[@B11]\]:

Statistics
----------

Data correlations were analyzed using the statistical method of Spearman. For direct data comparison the χ^2^-test was used.

Results
=======

In total, 37 patients (23 male, 14 female) with an average age of 28 years were treated with Rush-SIT against bee venom (59.5%), paperwasp venom (5.4%) and wasp venom (35.1%). According to their history, 91.9% of patients were admitted to the unit after experiencing an anaphylactic reaction (35.1% Mueller type II and 56.8% Mueller type III--IV) and 8.1% was treated after a mild skin reaction (Mueller type I) (Table [2](#T2){ref-type="table"}). The skin tests defined the diagnosis through intracutaneous test at concentrations of 0.01 μg/ml (32.4%), 0.1 μg/ml (64.9%) or 1 μg/ml (2.7%) (Table [2](#T2){ref-type="table"}).

###### 

Clinical data of patients who received stings I.

  Number of patients                             37
  ---------------------------------------------- ------------
  Sex                                            
  Males                                          23 (62.2%)
  Females                                        14 (37.8%)
  Middle age (years)                             28
  Range (years)                                  8 -- 52
  Grade of sting^\*^                             
  I                                              3 (8.1%)
  II                                             13 (35.1%)
  III--IV                                        21 (56.8%)
  Intra-cutaneous tests                          
  Lowest concentration eliciting the diagnosis   
  0.01 ìg/ml                                     12 (32.4%)
  0.1 μg/ml                                      24 (64.9%)
  1 μg/ml                                        1 (2.7%)
  Medication required                            
  Adrenaline                                     15 (45.4%)
  Antihistamines                                 7 (21.2%)
  Adr. + Antihist                                5 (15.2%)
  Both + Glucocorticoides                        1 (3.0%)
  No medication required                         5 (15.2%)

^\*^ Classified according to Mueller \[[@B11]\]: Grade I -- urticaria, pruritus, malaise; Grade II -- angioedema, chest tightness, nausea, vomiting, abdominal pain, dizziness; Grade III -- dispnoea, wheeze, stridor, dysphagia, hoarseness; Grade IV -- hypotension, collapse, loss of consciousness, incontinence, cyanosis.

During Rush-SIT,16 patients (43.2%) experienced minor reactions. These reactions were present once in 25%, twice in 18.75%, three times in 18.75% and more than three times in 37.5%. The reactions were found in 54.5% of patients treated with bee venom and in 30.8% in patients treated with wasp venom (no significance, n. s.) (Table [3](#T3){ref-type="table"}). The mean frequency of reactions/injections was 3.4% (33 reactions per 962 injections). The same index for the bee venom was 4.7% and the one for wasp venom was 1.5% (p \< 0.01). The mean absolute frequency of first degree reactions for bee venom treated patients was 0.50 and the one for patients treated with wasp venom was 0.31 (n. s.). The same index for the second degree was 0.73 for bee venom treated patients and 0.15 for wasp venom treated patients with a significant difference of p \< 0.01. Paperwasp treated patients experienced no anaphylactic reactions in the present study. Also, no Mueller type III or IV anaphylactic reaction was experienced. (Table [3](#T3){ref-type="table"}).

###### 

Clinical data of patients who received stings II.

                                                                    Total        Bee          Wasp        Paperwasp   P ^\#^
  ----------------------------------------------------------------- ------------ ------------ ----------- ----------- ---------
  Number of patients                                                37           22           13          2           
  Number of patients with allergic reactions during immunotherapy   16 (43.2%)   12 (54.5%)   4 (30.8%)   0           NS
  Reactions/injections                                              33 (3.4%)    27 (4.7%)    6 (1.5%)    0           \< 0.01
  Reactions/patients                                                                                                  
  I ^\*^                                                            15 (40.5%)   11 (50.0%)   4 (30.8%)   0           NS
  II                                                                18 (48.6%)   16 (72.7%)   2 (15.4%)   0           \< 0.01
  III--IV                                                           0 (0.0%)     0 (0.0%)     0 (0.0%)    0           

^\#^ Statistical comparison between bee and wasp venom treated patients. ^\*^ Classified according to Mueller\[[@B11]\]: Grade I -- urticaria, pruritus, malaise; grade II -- angioedema, chest tightness, nausea, vomiting, abdominal pain, dizziness; grade III -- dispnoea, wheeze, stridor, dysphagia, hoarseness; grade IV -- hypotension, collapse, loss of consciousness, incontinence, cyanosis.

The lowest dose causing a minor reaction was 5 μg (type I), the lowest dose for anaphylactic reactions (type II) was 20 μg with a peak at 60 μg and no raise in frequency in higher concentrations (Figure [1](#F1){ref-type="fig"}).

![Dose-dependency of reactions. The reactions were classiefied according to Mueller ^10^ with grade I -- urticaria, pruritus, malaise; grade II -- angioedema, chest tightness, nausea, vomiting, abdominal pain, dizziness; grade III -- dispnoea, wheeze, stridor, dysphagia, hoarseness, and grade IV -- hypotension, collapse, loss of consciousness, incontinence, cyanosis. Black: Mueller I, grey: Mueller II.](1471-5945-2-11-1){#F1}

These reactions were treated efficiently with adrenaline in 45.4%, antihistamines in 21.2%, with both in 15.2% and with costicosteroides (prednisolone) in combination with adrenaline and antihistamines in 3.0% of all cases. In 15.2% a treatment was not necessary. The use of epinephrine in type II reactions was more frequent than in type I reactions (20% of treated type I in contrast to 100% of type II (p \< 0.002)). 94.6% of the patients supported the end dose 100 μg venom.

Discussion
==========

The first documented anaphylactic reaction towards hymenoptera venom was the death of the Egyptian pharaoh Menes, who died according to an Egyptian hieroglyph in the year 2640 BC due to a wasp sting reaction \[[@B12]\], Since then, many treatment options were developed and tested. However, a specific preventive treatment has only been available since the pioneer works of Hunt et al. 1978. These studies demonstrated an almost complete protection by treatment with specific insect venom in contrast to earlier studies using whole body extracts which turned out to be equivalent to placebo \[[@B13]\].

The global extend of allergic diseases is still increasing with allergic diseases being a future threat even in developing countries,. However, only little is known on specific and preventive treatment in these countries due to economical reasons. Here we studied the possibility and adverse reactions of specific immunotherapy in Europe\'s least developed country Albania, using hymenoptera Rush-SIT.

The efficacy of Rush-SIT is well documented \[[@B5],[@B14],[@B15]\], but adverse reactions including anaphylactic reactions have been reported in up to 64% of all cases investigated \[[@B16]-[@B20]\].

Here we explored the occurrence of allergic reactions during Rush-SIT in a cohort of Albanian patients.

As immunotherapeutic scheme Rush-SIT was used, as this treatment form enables a hospital controlled administration of venom with a success of more than 95% \[[@B21]\].

Even if 43.2% of the patients experienced reactions during Rush-SIT, which is in accordance to previous reports \[[@B15],[@B22]\], the percentage related to the number of injections is only 3.4%.

Furthermore we found that during Rush-SIT, there was no significant difference of reactions/patient between *bee venom and wasp venom* treated patients in Mueller grade I. In contrast, in Mueller grade II there was a significant difference between bee venom and wasp venom treated patients. In this respect, the bee venom was found to be more aggressive than the wasp venoms, as indicated earlier \[[@B15],[@B21]\].

Minor anaphylactic reactions (Mueller grade I -- II) were present more frequent at the doses of 50 to 60 μg and patients who did not experience reactions up to this dose, did not respond to higher doses later. This may be explained from the fact that the quantity of venom in a sting is about 50 μg venom and an increased quantity such as the Rush-SIT end dose does not lead to an increased immune answer \[[@B23],[@B24]\].

For the therapy of allergic reactions during Rush-SIT, different drugs such as adrenaline, antihistamines or corticosteroides may be used. A possibility to prevent allergic reactions during Rush-SIT can be the preventive application of these drugs. Whereas adrenaline is suitable only for acute emergency medication in case of severe anaphylaxis, antihistamine medication only reduces cutaneous symptoms such urticaria effectively \[[@B25]\], but no anaphylactic situations. Therefore, the only efficient drugs for prevention anaphylaxis are corticosteroids which may be combined to antihistamines.

A recent retrospective study to determine the incidence and nature of adverse events associated with the induction of rush Hymenoptera venom immunotherapy in Australian patients demonstrated a high incidence of adverse systemic events during the induction phase \[[@B26]\]. Their conclusion, that immunotherapy should only be given by experienced staff in centres where there are facilities for resuscitation can be underlined by the present study. The therapy regimen should always be updated towards the standards published by internationally leading allergy centers.

Conclusions
===========

In summary, the present study describes the first investigation on the use of specific immunotherapy in a developing country such as Albania and proves that this treatment option may also be used in non-industrialized countries with an adverse reaction profile similar to western countries.
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